BusinessGlobal Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th American Society of Hematology (ASH) Annual MeetingBy Nasdaq OMXNov 1, 2017, 1:01 PM UTC
BusinessGlobal Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient with Severe and Symptomatic AnemiaBy Nasdaq OMXOct 28, 2017, 6:15 PM UTC
BusinessGlobal Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440By Nasdaq OMXOct 24, 2017, 12:01 PM UTC
BusinessGlobal Blood Therapeutics Announces Discontinuation of Idiopathic Pulmonary Fibrosis (IPF) ProgramBy Nasdaq OMXOct 23, 2017, 11:00 AM UTC
BusinessGlobal Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant GenotypeBy Nasdaq OMXOct 11, 2017, 12:00 PM UTC
BusinessGlobal Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in OctoberBy Nasdaq OMXOct 3, 2017, 12:01 PM UTC
BusinessGlobal Blood Therapeutics Announces New Employment Inducement GrantsBy Nasdaq OMXSep 26, 2017, 8:05 PM UTC
BusinessGlobal Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics ConferenceBy Nasdaq OMXSep 6, 2017, 12:01 PM UTC
